Psychiatry News

Suicide attempts among transgender and nonbinary youth increased significantly following the passage of state-level anti-transgender laws, study results in Nature Human Behavior suggested.

PHILADELPHIA — In this Healio Video Perspective from the Alzheimer’s Association International Conference, Johan Luthman, PhD, discusses new data from post hoc analyses evaluating the efficacy of Rexulti for Alzheimer’s-related agitation.

Adults with type 2 diabetes and opioid use disorder who received semaglutide had significantly lower risk for opioid overdose compared with those taking other diabetes medications, a research letter in JAMA Network Open showed.

Around one-third of former professional football players perceived themselves as having chronic traumatic encephalopathy, according to results from a cross-sectional study published in JAMA Neurology.

Although screen use before bedtime did not affect sleep onset or duration in children, using screens in bed not only impacted sleep quality but was also associated with cyberbullying and psychological distress, research showed.

Youth with chronic pain experience anxiety and depression symptoms more often and more intensely than their peers without chronic pain, according to findings published in JAMA Pediatrics.

The use of sodium-glucose cotransporter 2 inhibitors reduced the risk for multiple neurodegenerative diseases in adults with type 2 diabetes, according to study results published in Neurology.

A nurse-supported cognitive behavioral therapy intervention for insomnia reduced symptoms and improved sleep outcomes in veterans, results from a randomized study published in JAMA Internal Medicine showed.

With more than 13 million U.S. adults having seriously considered suicide last year, the National Strategy for Suicide Prevention plan released in April uses a comprehensive approach to prevent suicide, according to an HHS statement.

Among young adults aged 19 to 30 years and early midlife adults aged 35 to 50 years, past-year use of cannabis and hallucinogens remained at “historically high” levels in 2023, according to the Monitoring the Future Panel Study Annual Report.